October 26, 2026: PSM files citizen petition asking FDA not to allow compounding of peptides

Patient Safety Group Petitions FDA to Bar Compounding of Peptide Drugs

The Partnership for Safe Medicines (PSM), a nonprofit advocacy coalition focused on drug safety and counterfeit medication risks, filed a citizen petition with the U.S. Food and Drug Administration on October 26, 2026, urging the agency not to permit pharmacy compounding of peptide-based drugs, according to the organization. The filing adds a new flashpoint to an already contentious regulatory debate over compounded versions of popular peptide medications, including GLP-1 receptor agonists used for weight loss and diabetes management.

Details of the petition's full legal arguments were not immediately available in public reporting, but the filing follows a pattern of citizen petitions submitted to the FDA by stakeholders on multiple sides of the compounding debate over the past several years. PSM has previously raised concerns about the safety risks associated with compounded drugs, particularly those manufactured outside the traditional pharmaceutical supply chain.

What Is a Citizen Petition?

Under FDA regulations, specifically 21 CFR 10.30, any individual or organization may formally petition the agency to take or refrain from taking a specific administrative action. Citizen petitions are a recognized mechanism for influencing FDA policy outside of litigation or formal rulemaking, and the agency is legally required to respond, though response timelines often stretch for months or even years.

Citizen petitions have become an increasingly common tool in the fight over peptide compounding. Pharmaceutical manufacturers, compounding pharmacies, trade associations, and patient advocacy groups have all used the process to try to shape how the FDA treats semaglutide, tirzepatide, and other peptide compounds under its regulatory authority.

Background: The Peptide Compounding Controversy

The debate over peptide compounding intensified following widespread shortages of branded GLP-1 medications such as Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound. During periods when these drugs appeared on the FDA's drug shortage list, federal law permitted licensed compounding pharmacies to produce versions of the active ingredients to meet patient demand under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Once the FDA removed semaglutide and tirzepatide from the shortage list, compounders were generally required to stop producing copies of those specific drugs, though legal challenges and exceptions have continued. Manufacturers including Novo Nordisk and Eli Lilly have pursued litigation against compounding pharmacies and telehealth companies they allege sold unauthorized or unsafe versions of their products.

PSM's petition appears to extend this fight beyond the shortage-driven exception, asking the FDA to categorically restrict compounding of peptide drugs as a class, rather than addressing them on a drug-by-drug or shortage-specific basis.

Why This Matters for the Peptide Industry

• Market impact: A broad FDA restriction on peptide compounding could significantly affect compounding pharmacies, telehealth platforms, and wellness clinics that have built business models around offering lower-cost alternatives to branded peptide drugs.
• Patient access: Advocates for compounding argue that restricting access could push patients back toward expensive branded drugs or toward unregulated gray-market sources, potentially increasing safety risks rather than reducing them.
• Safety concerns: PSM and similar groups have historically argued that compounded peptides lack the manufacturing oversight, purity testing, and quality controls required for FDA-approved drugs, raising risks of contamination, dosing errors, or counterfeit ingredients.
• Precedent-setting: A decision addressing peptides as a drug category, rather than individual products, could set a broader precedent for how FDA treats future biologic and peptide-based compounding requests.

What This Means for Readers

For patients currently using compounded peptide medications, the petition itself does not immediately change anything. The FDA is required to respond to citizen petitions but is not bound to any specific timeline for a final decision, and the agency may take months or longer to issue a substantive response. In the meantime, existing rules governing compounded peptides—including shortage-based exceptions and state pharmacy board oversight—remain in effect.

Patients and healthcare providers should understand that citizen petitions reflect advocacy positions, not FDA policy. The filing signals that PSM believes current regulatory distinctions between approved and compounded peptide products are insufficient, but it does not constitute a ban or new rule.

What to Watch For

Observers should monitor several developments in the coming months:

• Whether the FDA formally dockets the petition and opens it for public comment, which would allow compounding pharmacies, manufacturers, and medical groups to respond.
• Any statements from compounding industry trade groups, such as the Alliance for Pharmacy Compounding, pushing back on PSM's request.
• Parallel litigation involving branded manufacturers and compounders that could influence how the FDA approaches the petition.
• Any FDA guidance updates regarding peptide drugs generally, including bulk drug substance list determinations under Section 503A.

As the petition moves through the regulatory process, it is likely to become a focal point in the broader national conversation about balancing drug affordability, patient access, and pharmaceutical safety standards.

This article is for informational purposes only and does not constitute legal or medical advice. Readers seeking guidance on specific medications or regulatory matters should consult a qualified attorney or healthcare provider. Details regarding the citizen petition are based on available reporting from the Partnership for Safe Medicines and general FDA regulatory procedures as of publication.